Rossari Biotech credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
40840818810673.9
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
28128173.538.0−76.6
0.31×0.31×0.16×0.10×0.08×
0.21×0.21×0.06×0.04×−0.08×
1.43×1.43×0.71×0.42×0.33×
0.89×0.98×0.28×0.15×−0.34×
7.24×7.24×11.12×9.78×7.17×
22.5%23.4%13.7%9.2%7.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ROSSARI₹407.60

Rossari Biotech Limited

· Chemicals
₹ CrorePeersNOCILHSCLNAVINFLUORDDEVPLSTIKCHEMPLASTSTATACHEMAARTIINDJGCHEMMcap ₹2,257 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt73.9105.8188.0408.0408.0
Net Debt-76.638.073.5280.7280.7
Total Debt/Equity0.080.100.160.310.31
Net Debt/Equity-0.080.040.060.210.21
Total Debt/EBITDA0.330.420.711.431.43
Net Debt/EBITDA-0.340.150.280.980.89
Interest Coverage (EBIT/Interest)7.179.7811.127.247.24
Total Debt/Total Capital %7.479.1713.6923.4322.47
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.